MA45692B1 - Blood plasma fractions used as treatment for cognitive disorders associated with aging - Google Patents

Blood plasma fractions used as treatment for cognitive disorders associated with aging

Info

Publication number
MA45692B1
MA45692B1 MA45692A MA45692A MA45692B1 MA 45692 B1 MA45692 B1 MA 45692B1 MA 45692 A MA45692 A MA 45692A MA 45692 A MA45692 A MA 45692A MA 45692 B1 MA45692 B1 MA 45692B1
Authority
MA
Morocco
Prior art keywords
aging
treatment
blood plasma
disorders associated
cognitive disorders
Prior art date
Application number
MA45692A
Other languages
French (fr)
Other versions
MA45692A (en
Inventor
Vu Dang
Ian Gallager
Steven P Braithwaite
S Sakura Minami
Joe Mccracken
Karoly Nikolich
David Bell
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MA45692A publication Critical patent/MA45692A/en
Publication of MA45692B1 publication Critical patent/MA45692B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur des procédés et des compositions pour traiter et/ou prévenir des états liés au vieillissement. Les compositions utilisées dans les procédés comprennent des fractions dérivées du plasma sanguin ayant une efficacité dans le traitement et/ou la prévention d'états liés au vieillissement tels que des troubles neurocognitifs.Disclosed are methods and compositions for treating and / or preventing conditions related to aging. Compositions used in the methods include moieties derived from blood plasma having efficacy in the treatment and / or prevention of aging-related conditions such as neurocognitive disorders.

MA45692A 2016-08-18 2017-04-27 Blood plasma fractions used as treatment for cognitive disorders associated with aging MA45692B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376529P 2016-08-18 2016-08-18
US201662412258P 2016-10-24 2016-10-24
PCT/US2017/029953 WO2018034712A1 (en) 2016-08-18 2017-04-27 Blood plasma fractions as a treatment for aging-associated cognitive disorders

Publications (2)

Publication Number Publication Date
MA45692A MA45692A (en) 2019-05-22
MA45692B1 true MA45692B1 (en) 2021-10-29

Family

ID=61196950

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45692A MA45692B1 (en) 2016-08-18 2017-04-27 Blood plasma fractions used as treatment for cognitive disorders associated with aging

Country Status (28)

Country Link
US (2) US20190321449A1 (en)
EP (2) EP3484502B1 (en)
JP (3) JP7316931B2 (en)
KR (3) KR20220107322A (en)
CN (2) CN109963582B (en)
AU (3) AU2017312722B2 (en)
BR (1) BR112019003172A2 (en)
CA (1) CA3033051A1 (en)
CL (1) CL2019000304A1 (en)
CY (1) CY1124695T1 (en)
DK (1) DK3484502T3 (en)
ES (1) ES2899147T3 (en)
HR (1) HRP20211628T1 (en)
HU (1) HUE056294T2 (en)
IL (2) IL264660B2 (en)
LT (1) LT3484502T (en)
MA (1) MA45692B1 (en)
MD (1) MD3484502T2 (en)
MX (1) MX2019001718A (en)
NZ (1) NZ750885A (en)
PL (1) PL3484502T3 (en)
PT (1) PT3484502T (en)
RS (1) RS62558B1 (en)
SG (1) SG11201901273TA (en)
SI (1) SI3484502T1 (en)
UA (1) UA126232C2 (en)
WO (1) WO2018034712A1 (en)
ZA (1) ZA202004834B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709098B (en) * 2017-04-26 2024-01-30 万能溶剂有限公司 Dosing regimen for treatment of cognitive and movement disorders with plasma and plasma preparations
CA3097083A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
CN110787187B (en) * 2018-07-16 2022-05-13 北京豪思生物科技股份有限公司 Blood plasma mixture for enhancing memory and cognitive function and preparation method and application thereof
CN110724176B (en) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 Plasma protein isolate for treating Alzheimer's disease and preparation method and application thereof
SG11202100347QA (en) * 2018-07-20 2021-02-25 Alkahest Inc Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CN113056275A (en) * 2018-10-26 2021-06-29 万能溶剂有限公司 Use of plasma and plasma fractions for improving pain, wound healing and post-operative recovery
CN110448686B (en) * 2019-09-19 2022-11-04 北京豪思生物科技股份有限公司 Application of ceruloplasmin combined with transferrin
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
AU2020388572A1 (en) 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases
WO2024102244A1 (en) * 2022-11-11 2024-05-16 Alkahest, Inc. Blood plasma fractions for improvement of myelination

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3612137A1 (en) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh STERILE PLASMA REPLACEMENT
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
JP4402885B2 (en) * 2001-05-11 2010-01-20 財団法人化学及血清療法研究所 Novel therapeutic agent for neurodegenerative diseases
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
ES2257225B1 (en) 2006-02-17 2007-03-16 Grifols, S.A THERAPEUTIC PREPARATION OF FVIIA OF VERY HIGH PURITY AND METHOD FOR OBTAINING IT.
ES2332846B1 (en) * 2007-10-26 2010-07-08 Grifols, S.A. USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS.
PL2271382T3 (en) 2008-04-15 2013-08-30 Grifols Therapeutics Inc Two-stage ultrafiltration/diafiltration
US20090297485A1 (en) 2008-05-28 2009-12-03 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3552624A1 (en) 2013-05-06 2019-10-16 Baxalta Incorporated Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
WO2015088915A1 (en) * 2013-12-09 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
ES2524516B1 (en) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Preparation procedure of human albumin with reduced dissolved oxygen level
US10525107B2 (en) * 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
CN110709098B (en) * 2017-04-26 2024-01-30 万能溶剂有限公司 Dosing regimen for treatment of cognitive and movement disorders with plasma and plasma preparations
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Also Published As

Publication number Publication date
UA126232C2 (en) 2022-09-07
CA3033051A1 (en) 2018-02-22
LT3484502T (en) 2021-12-10
PL3484502T3 (en) 2022-01-31
WO2018034712A1 (en) 2018-02-22
KR20190032614A (en) 2019-03-27
JP2023156459A (en) 2023-10-24
HUE056294T2 (en) 2022-02-28
SG11201901273TA (en) 2019-03-28
CN109963582B (en) 2022-12-27
US20220152161A1 (en) 2022-05-19
IL304946A (en) 2023-10-01
JP7316931B2 (en) 2023-07-28
MX2019001718A (en) 2019-09-13
ES2899147T3 (en) 2022-03-10
AU2020200181A1 (en) 2020-01-30
JP2019528269A (en) 2019-10-10
CL2019000304A1 (en) 2019-05-31
US20190321449A1 (en) 2019-10-24
AU2017312722B2 (en) 2020-01-02
CY1124695T1 (en) 2022-07-22
EP3484502A1 (en) 2019-05-22
AU2021240142A1 (en) 2021-10-28
MD3484502T2 (en) 2022-01-31
EP3484502A4 (en) 2020-03-04
RS62558B1 (en) 2021-12-31
EP3484502B1 (en) 2021-08-25
DK3484502T3 (en) 2021-10-25
AU2017312722A1 (en) 2019-03-14
AU2021240142B2 (en) 2024-06-20
JP7447069B2 (en) 2024-03-11
IL264660A (en) 2019-04-30
CN115957309A (en) 2023-04-14
KR20240036720A (en) 2024-03-20
PT3484502T (en) 2021-11-18
JP2022037124A (en) 2022-03-08
HRP20211628T1 (en) 2022-02-04
MA45692A (en) 2019-05-22
IL264660B2 (en) 2024-03-01
KR20220107322A (en) 2022-08-02
CN109963582A (en) 2019-07-02
AU2020200181B2 (en) 2021-07-22
ZA202004834B (en) 2022-07-27
SI3484502T1 (en) 2022-01-31
NZ750885A (en) 2021-07-30
IL264660B1 (en) 2023-11-01
EP3995140A1 (en) 2022-05-11
BR112019003172A2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
MA45692B1 (en) Blood plasma fractions used as treatment for cognitive disorders associated with aging
FR22C1063I1 (en) THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF HIV VIRUS INFECTION
MA50417A (en) METHODS OF USING EHMT2 INHIBITORS IN THE TREATMENT OR PREVENTION OF BLOOD DISORDERS
MA42560B1 (en) Compositions comprising bacterial strains of blautia for the treatment of visceral hypersensitivity
MA50786A (en) COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
ZA202301009B (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
SA519400950B1 (en) Compositions and Methods of Inhibiting MASP-3 for The Treatment of Various Diseases and Disorders
MA41013A (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
MA43335B1 (en) Transthyretin (ttr) arni compositions and methods for use thereof for the treatment or prevention of diseases associated with ttr
MA40454B1 (en) Gamma-diketones for the treatment and prevention of wrinkles and aging of the skin
MA43982A (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES
MA40768B1 (en) Mono or di-substituted indole derivatives as dengue virus replication inhibitors
MA45811A (en) METHODS AND COMPOSITIONS OF TREATMENT OF DISEASE.
MA45496A (en) NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
MA46619B1 (en) Anti-il-33 antibodies and their uses
MA39722A (en) COMPOSITION FOR USE IN A METHOD FOR THE TREATMENT OR PREVENTION OF ANEMIA BY INHIBITION OF ACTIVIN B AND GDF11
MA52961A (en) COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF INFLAMMATION
MA45226A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF OXALATE RELATED CONDITIONS
MX2019004859A (en) Combination treatments comprising administration of imidazopyrazinones.
MA51613A (en) POLYTHERAPY FOR THE TREATMENT OR PREVENTION OF CANCER
MX2021000707A (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products.
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
MA52960A (en) COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF FIBROSIS
FR3075038B1 (en) USE OF FLUOROETHYLNORMEMANTINE FOR THE PREVENTION OF THE APPEARANCE AND THE TREATMENT OF ANXIETY
FR3070263B1 (en) COMPOSITION FOR ITS USE IN THE TREATMENT AND / OR PREVENTION OF INFERTILITY